Final Berkshire Biomedical Webinar to Spotlight Transformational Potential of COPA™ Across High-Need Conditions

Dallas, Texas, April 18, 2025 (GLOBE NEWSWIRE) —

As Berkshire Biomedical nears the shut of its fairness crowdfunding marketing campaign on StartEngine, the corporate will host its ultimate investor-focused webinar on Thursday, April 24, at 1:30 PM PST. The session will supply a deeper have a look at how Berkshire’s COPA™ (Computerized Oral Prescription Administration) know-how may handle pressing challenges in remedy security, adherence, and misuse throughout a variety of therapeutic classes.

Whereas Berkshire’s preliminary market focus for COPA will probably be  for Remedy for Opioid Use Dysfunction (MOUD), its precision, management, and real-time connectivity might have far-reaching purposes. The upcoming webinar will discover its potential use in treating power ache, ADHD, epilepsy, Alzheimer’s illness, and supporting post-surgical restoration, with a concentrate on decreasing threat, enhancing outcomes, and enabling safe, customized care.

John Timberlake, President and CEO of Berkshire Biomedical, will lead the dialogue alongside Tom King, Senior Advisor to the Firm. The audio system can even study COPA’s potential worth to scientific analysis organizations and pharmaceutical companions as a digital drug supply platform for scientific trials and high-risk drugs.

Attendees will hear how the COPA platform may assist sufferers, caregivers, and care groups alike—and the way its integration into scientific and business settings may unlock strategic partnerships, licensing, and future institutional development alternatives.

That is the ultimate alternative to have interaction straight with firm management earlier than Berkshire Biomedical’s StartEngine marketing campaign closes.

REGISTER NOW FOR THE WEBINAR

About Berkshire Biomedical Company

Berkshire Biomedical Company is a privately held medical system firm. Berkshire is pioneering the usage of biometric applied sciences, mixed with encrypted HIPAA-compliant cloud-based and healthcare provider-enabled distant administration programs, to supply exact and correct customized remedy supply to solely the Authenticated Meant Consumer (AIU).

The Firm’s lead product underneath growth, the Computerized Oral Prescription Administration System (COPA), is a hand-held, automated, customized oral liquid allotting system designed and supposed to ship managed and non-controlled liquid oral drugs to solely the AIU upon affirmation of twin biometric identification (fingerprint and dentition).

Upon receiving regulatory authorization, the Firm intends to initially search alternatives to leverage COPA within the supply and distant administration of oral liquid remedy methadone, for Remedy Use for Opioid Use Dysfunction therapy and subsequently for the supply of managed drugs for the therapy of ache, as these sufferers have the best want for the advantages of COPA’s options.

As beforehand introduced, the Firm has developed COPA with the assist of a $2.0 million Quick-Monitor Small Enterprise Innovation Analysis grant from the Nationwide Institute on Drug Abuse of the Nationwide Institutes of Well being underneath award quantity R44DA057185.

Sooner or later, the corporate will look to increase COPA utilization right into a broader set of drug therapeutics and potential scientific purposes, in addition to with firms that make the most of and commercialize knowledge analytics offered by digital units to enhance outcomes and scale back threat.

The COPA System is at the moment underneath growth, has NOT been reviewed by the U.S. Meals and Drug Administration, and isn’t obtainable for business sale.